AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31010033
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of BPH
Trial: 31010033
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VitD3 and BPH
Trial: 27043168
Drug: Gabapentin 100-300
RxNorm normalized name: gabapentin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 100-300 mg after each HD session for one month
Trial: 15326195
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus a new agent
Trial: 15326195
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus a new agent
Trial: 9510218
Drug: m-chlorophenylpiperazine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m-chlorophenylpiperazine (0.1 mg/kg intravenously)
Trial: 2909150
Drug: Aminophylline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (3 mg/kg over 3 minutes)
Trial: 2909150
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 ml of saline over 3 minutes)
Trial: 1572446
Drug: Flurbiprofen 150
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 150 mg
Trial: 6348714
Drug: Flurbiprofen 100
RxNorm normalized name: flurbiprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 100 mg
Trial: 26214039
Drug: Dengue vaccine
RxNorm normalized name: Dengue vaccine
DrugBank: Dengue tetravalent vaccine, live (DB14764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue vaccine
Trial: 31436378
Drug: Lactic acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic acid 5% mouth wash 3 times daily
Trial: 31436378
Drug: Kenalog in
RxNorm normalized name: Kenalog in Orabase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kenalog in Orabase twice daily
Trial: 30942009
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (conventional patient controlled epidural analgesia and oral celecoxib)
Trial: 25740292
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (40 mg day -1)
Trial: 7620686
Drug: Base preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base preparation (vehicle)
Trial: 2134659
Drug: He‐Ne‐Laser treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: He‐Ne‐Laser treatment
Trial: 30763
Drug: Lorazepam (3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (3.1 mg daily, b.i.d.)
Trial: 11474638
Drug: r-hGH therapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hGH therapy for 6-12 months
Trial: 9701130
Drug: 2‐component acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐component acellular pertussis vaccine
Trial: 9701130
Drug: 5‐component acellular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐component acellular pertussis vaccine
Trial: 9701130
Drug: Whole‐cell pertussis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole‐cell pertussis vaccine
Trial: 7958670
Drug: Sham feeding-induced
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham feeding-induced acid secretion during lox infusion
Trial: 3117554
Drug: Buccal nitroglycerin
RxNorm normalized name: nitroglycerin Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal nitroglycerin (2.5 mg in 49% and 5.0 mg in 51%)
Trial: 22768661
Drug: Alfacalcidol with
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol with 400 mg of elemental calcium daily for 12 months
Trial: 22768661
Drug: Menatetrenone with
RxNorm normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone with 400 mg of elemental calcium daily for 12 months
Trial: 20547822
Drug: Bilateral ultrasound-guided
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral ultrasound-guided TAP blocks (2 x 20 mL 0.5% ropivacaine)
Trial: 30364565
Drug: Cardiac resynchronisation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronisation therapy (CRT)
Trial: 31302353
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment alone
Trial: 15973773
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CTX) by intermission intravenous pulse with prednisone
Trial: 11841992
Drug: Intravenous GLP-1
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GLP-1
Trial: 27487253
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (30 mg twice daily)
Trial: 27487253
Drug: TEG‐adjusted enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEG‐adjusted enoxaparin dosing (35 mg twice daily)
Trial: 25527750
Drug: Polydextrose (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydextrose (21 g/d)
Trial: 22649263
Drug: Soluble corn
RxNorm normalized name: soluble corn fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble corn fiber (SCF; 21 g/d)
Trial: 18057215
Drug: Pioglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone treatment in patients with CKD
Trial: 18057215
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in patients with CKD
Trial: 16688995
Drug: Shexiang Injection
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
DrugBank: Moschus berezovskii musk sac resin (DB14247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Injection (SI) plus conventional therapy
Trial: 10750647
Drug: Doxorubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (50 mg/m2 every 4 weeks) + Tamoxifen (30 mg bid)
Trial: 2125857
Drug: Ritanserin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritanserin (30 mg daily p.o.)
Trial: 2125857
Drug: Orphenadrine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orphenadrine (150 mg daily p.o.)
Trial: 31083802
Drug: Direct acting
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct acting antiviral (DAA) therapy for hepatitis C
Trial: 31083802
Drug: Direct acting
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct acting antiviral (DAA) therapy for hepatitis C in cirrhotic patients
Trial: 31083802
Drug: Direct acting
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct acting antiviral (DAA) therapy for hepatitis C in non-cirrhotic patients
Trial: 31083802
Drug: Direct acting
RxNorm normalized name: DIRECT ACTING ANTIVIRALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct acting antiviral (DAA) therapy for hepatitis C in patients without end-of-treatment response (EoTR)
Trial: 26154029
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with 0.2 g/L 2'FL
Trial: 26154029
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with 1.0 g/L 2'FL
Trial: 26456812
Drug: Chemotherapy (primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (primary treatment for ovarian cancer)
Trial: 18445839
Drug: Pharmacokinetically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetically guided FU dose adjustment (arm B)
Trial: 18445839
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing of fluorouracil (arm A)
Trial: 8773160
Drug: Baseline oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline oral glucose tolerance test (GTT)
Trial: 3883729
Drug: Propranolol (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (60 to 120 mg daily)
Trial: 30165520
Drug: Lower LT4
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lower LT4 dose
Trial: 30165520
Drug: Perceived higher
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived higher LT4 doses
Trial: 27424010
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (2.4 g/day for 8 weeks)
Trial: 24448120
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg/day
Trial: 16481597
Drug: Minocycline 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 200 mg/day
Trial: 9583547
Drug: Paravertebral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paravertebral administration of bupivacaine
Trial: 9583547
Drug: Interpleural administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interpleural administration of bupivacaine
Trial: 2534170
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of cefotaxime during resection and another 1 g dose when the bladder catheter was removed
Trial: 2534170
Drug: no additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no additional cefotaxime dose when the bladder catheter was removed
Trial: 22129569
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) cilostazol 200 mg × 1 tablet, once daily
Trial: 22129569
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) cilostazol 100 mg × 2 tablets, BID
Trial: 22129569
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) cilostazol 200 mg × 1 tablet, once daily (fed state)
Trial: 22129569
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of SR and IR formulations for 8 consecutive days
Trial: 19189982
Drug: Levobupivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 10 mg h(‐1) at 0.5% concentration with sufentanil 2.6 microg h(‐1)
Trial: 19189982
Drug: Levobupivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 10 mg h(‐1) at 0.25% concentration with sufentanil 2.6 microg h(‐1)
Trial: 19189982
Drug: Levobupivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 10 mg h(‐1) at 0.15% concentration with sufentanil 2.6 microg h(‐1)
Trial: 8435884
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 g four times per day)
Trial: 2071268
Drug: Imidazole salicylate
RxNorm normalized name: imidazole salicylate
DrugBank: Imidazole salicylate (DB13860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidazole salicylate (750 mg t.i.d.)
Trial: 2071268
Drug: Ibuprofen (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (400 mg t.i.d.)
Trial: 28827188
Drug: Capecitabine-containing treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine-containing treatment (ATX)
Trial: 27956003
Drug: Anacetrapib 100
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib 100 mg
Trial: 12556405
Drug: BQ-123 (ET(A)
RxNorm normalized name: ethanol
DrugBank: BQ-123 (DB12054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BQ-123 (ET(A) receptor antagonist)
Trial: 2383162
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g/d intravenously for 2 weeks
Trial: 2383162
Drug: Ceftriaxone (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (after initial placebo treatment)
Trial: 6454249
Drug: Dicloxacillin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicloxacillin administration for 6 days per- and postoperatively
Trial: 29258928
Drug: Combined intravenous‐inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous‐inhalation anesthesia
Trial: 17486027
Drug: Activated device
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated device treatment for 10 minutes (PDE study)
Trial: 17486027
Drug: Activated device
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated device treatment for 10 minutes (SS study)
Trial: 8640706
Drug: Adjuvant Active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Active Specific Immunotherapy (ASI) with 3 intradermal injections of 10^7 autologous irradiated tumor cells mixed with 10^7 Bacillus Calmette‐Guèrin
Trial: 8640706
Drug: Adjuvant Active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant Active Specific Immunotherapy (ASI)
Trial: 19158317
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg daily for 4 weeks)
Trial: 11893233
Drug: Prolonged-release alfuzosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release alfuzosin 10mg once daily
Trial: 7357232
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment (conversation training programme)
Trial: 7357232
Drug: Behavioural treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural treatment control
Trial: 17605771
Drug: Multidisciplinary assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary assessment and treatment of multifactorial fall risk factors.
Trial: 15646610
Drug: Oraqix anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oraqix anesthetic gel
Trial: 9724256
Drug: Amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 50 mg for 21 days
Trial: 7831626
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (BA+CS)
Trial: 6487494
Drug: Amitriptyline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50 mg)
Trial: 31597460
Drug: Higher-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose edoxaban regimen (60/30 mg daily)
Trial: 31597460
Drug: Lower-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose edoxaban regimen (30/15 mg daily)
Trial: 28240714
Drug: 3% glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% glycerol solution containing 26 ml·kg of water and 1 g·kg of glycerol
Trial: 28240714
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group drinking 26 ml·kg of water
Trial: 14515286
Drug: PCA (patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA (patient-controlled analgesia) with morphine
Trial: 7705704
Drug: Dose level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 4 (22.5 mg/m2 FUDR and 6.75 mg/m2 cisplatin)
Trial: 2649463
Drug: Misonidazole (MISO)
RxNorm normalized name: Metronidazole
DrugBank: Misonidazole (DB11716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misonidazole (MISO) 12 g/m2 applied within 6 weeks
Trial: 17537771
Drug: CPAP titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP titration night
Trial: 21277706
Drug: Placebo (flavor-matched,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (flavor-matched, tobacco-free preparation)
Trial: 17728549
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment approaches (laser photocoagulation, PDT, subretinal surgery, novel anti-angiogenic drugs)
Trial: 7995624
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (to raise plasma insulin 100 microU/mL)
Trial: 3294036
Drug: Slow-release terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release terbutaline (b.i.d. 0.25 mg/kg per day)
Trial: 3294036
Drug: Slow-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release theophylline (5.31 mg/kg morning and 10.62 mg/kg evening)
Trial: 22188590
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 100 μg twice daily (BD)
Trial: 22188590
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 200 μg OD
Trial: 22188590
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 100 μg BD
Trial: 16208143
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (nutritional doses)
Trial: 11712619
Drug: Amisulpride (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (50 mg o.d.)
Trial: 11712619
Drug: Sertraline (50‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50‐100 mg o.d.)
Trial: 9446006
Drug: No calcium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No calcium channel blockers (III, n = 17)
Trial: 31132111
Drug: FOLFOX +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX + 2 g oral curcumin/d (CUFOX)
Trial: 26818096
Drug: 15-mg mirtazapine
RxNorm normalized name: mirtazapine 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mg mirtazapine (n = 8)
Trial: 18265647
Drug: OS‐1 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OS‐1 (oral rehydration solution)
Trial: 18265647
Drug: KN3B (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN3B (intravenous maintenance solution)
Trial: 12960999
Drug: L-arginine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (200 mg/kg infused intravenously over 4 hours, 12 and 3 hours before PCI, and 500 mg over 10 minutes prior to stent implantation, followed by oral supplementation of 6 g/day for 14 days after PCI)
Trial: 9689421
Drug: Pentaerithritol tetranitrate
RxNorm normalized name: pentaerithrityl tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaerithritol tetranitrate (PETN) 240 mg/d
Trial: 9689421
Drug: Pentaerithritol tetranitrate
RxNorm normalized name: pentaerithrityl tetranitrate
DrugBank: Pentaerythritol tetranitrate (DB06154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentaerithritol tetranitrate (PETN) 150 mg/d
Trial: 7532087
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (6 million kallikrein inactivator units)
Trial: 7532087
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (3 million kallikrein inactivator units)
Trial: 7532087
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (3 million kallikrein inactivator units) with autologous blood transfusions
Trial: 2673045
Drug: Sequential methotrexate-5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential methotrexate-5-fluorouracil (MF)
Trial: 28497259
Drug: Intravenous valproic
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous valproic acid (15 to 150 mg/kg)
Trial: 27598804
Drug: Short-term androgen
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term androgen deprivation (STAD) combined with high-dose radiation therapy (HDRT)
Trial: 18845605
Drug: Goal setting
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goal setting and individualised activities of daily living activity programme by a gerontology nurse, reinforced by usual healthcare assistants
Trial: 16117862
Drug: Intracoronary injection
RxNorm normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary injection of bone‐marrow cells (BMCs)